CL2022002568A1 - Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa alfa5 - Google Patents
Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa alfa5Info
- Publication number
- CL2022002568A1 CL2022002568A1 CL2022002568A CL2022002568A CL2022002568A1 CL 2022002568 A1 CL2022002568 A1 CL 2022002568A1 CL 2022002568 A CL2022002568 A CL 2022002568A CL 2022002568 A CL2022002568 A CL 2022002568A CL 2022002568 A1 CL2022002568 A1 CL 2022002568A1
- Authority
- CL
- Chile
- Prior art keywords
- naphthyridine
- pyrido
- alpha5
- receptor modulators
- pyridazine derivatives
- Prior art date
Links
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 title 1
- DVXYZLCJSYRIPC-UHFFFAOYSA-N pyrido[3,4-c]pyridazine Chemical class C1=NN=C2C=NC=CC2=C1 DVXYZLCJSYRIPC-UHFFFAOYSA-N 0.000 title 1
- 102000027484 GABAA receptors Human genes 0.000 abstract 2
- 108091008681 GABAA receptors Proteins 0.000 abstract 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract 1
- 230000003281 allosteric effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona compuestos de la fórmula (I) y/o sales de este y/o metabolitos biológicamente activos de este y/o profármacos de este y/o solvatos de este y/o hidratos de este y/o polimorfos de este que tienen afinidad y selectividad por el receptor A subunidad alfa5 del ácido gamma-aminobutírico y actúan como moduladores alostéricos positivos del receptor GABAA alfa5, lo que les permite ser útiles en el tratamiento o la prevención de enfermedades relacionadas con el receptor GABAA alfa5, en el proceso para la preparación de estos y en los productos intermedios de la preparación de estos, en las composiciones farmacéuticas que los comprenden solos o en combinación con uno o más principios activos diferentes y en su uso como medicamentos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUP2000113 | 2020-03-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002568A1 true CL2022002568A1 (es) | 2023-03-24 |
Family
ID=89666363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002568A CL2022002568A1 (es) | 2020-03-26 | 2022-09-22 | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa alfa5 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240067637A1 (es) |
| EP (1) | EP4126859A1 (es) |
| JP (1) | JP2023520647A (es) |
| KR (1) | KR20220160061A (es) |
| CN (1) | CN115348962A (es) |
| AR (1) | AR121666A1 (es) |
| AU (1) | AU2021244926A1 (es) |
| BR (1) | BR112022019128A2 (es) |
| CA (1) | CA3171441A1 (es) |
| CL (1) | CL2022002568A1 (es) |
| CO (1) | CO2022014877A2 (es) |
| CU (1) | CU20220058A7 (es) |
| EC (1) | ECSP22082367A (es) |
| IL (1) | IL296716A (es) |
| JO (1) | JOP20220219A1 (es) |
| MX (1) | MX2022011933A (es) |
| PE (1) | PE20221836A1 (es) |
| TW (1) | TW202202495A (es) |
| WO (1) | WO2021191838A1 (es) |
| ZA (1) | ZA202211414B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP2100338A1 (hu) * | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2728900B1 (fr) * | 1994-12-29 | 1997-01-31 | Synthelabo | Derives de 3-phenylisoquinolein-1(2h)-one, leur preparation et leur application en therapeutique |
| SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| EP1937674A1 (en) * | 2005-10-11 | 2008-07-02 | F.Hoffmann-La Roche Ag | Isoxazole derivatives |
| KR101103129B1 (ko) * | 2005-11-09 | 2012-01-04 | 에프. 호프만-라 로슈 아게 | 3-아릴-아이속사졸-4-카본일-벤조퓨란 유도체 |
| HU230518B1 (hu) | 2005-12-20 | 2016-10-28 | Richter Gedeon Nyrt. | Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények |
| HUP0600810A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600809A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them |
| HUP0600808A3 (en) | 2006-10-27 | 2008-09-29 | Richter Gedeon Nyrt | New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| US8742097B2 (en) * | 2010-11-09 | 2014-06-03 | Hoffmann-La Roche Inc. | Triazole compounds I |
| CA2828578A1 (en) * | 2011-03-04 | 2012-09-13 | Lexicon Pharmaceuticals, Inc. | Mst1 kinase inhibitors and methods of their use |
| WO2012129344A1 (en) | 2011-03-23 | 2012-09-27 | Amgen Inc. | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
| US9475797B2 (en) | 2012-06-26 | 2016-10-25 | Saniona A/S | Phenyl triazole derivative and its use for modulating the GABAA receptor complex |
| WO2014001279A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| CN104411699B (zh) * | 2012-06-26 | 2017-06-13 | 萨尼奥纳有限责任公司 | 苯基三唑衍生物及其用于调节gabaa 受体复合体的用途 |
| WO2014001278A1 (en) | 2012-06-26 | 2014-01-03 | Aniona Aps | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| CN102924452B (zh) * | 2012-11-16 | 2015-01-21 | 苏州施亚生物科技有限公司 | 5,6,7,8-四氢-2H-吡啶并[3,4-c]哒嗪-3-酮的合成方法 |
| HUP1300139A2 (en) | 2013-03-06 | 2014-09-29 | Richter Gedeon Nyrt | Phenoxypiperidine h3 antagonists |
| NZ722077A (en) | 2013-12-20 | 2021-12-24 | Agenebio Inc | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| US9296747B1 (en) * | 2014-10-10 | 2016-03-29 | Allergan, Inc. | Piperidylpyrimidine derivatives as modulators of protein kinase inhibitors and of vascular endothelial growth factor receptor 2 |
| EP3323809A4 (en) * | 2015-06-22 | 2019-01-02 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic heterocyclic amide derivative |
| EP3341369A1 (en) | 2015-08-28 | 2018-07-04 | AbbVie Inc. | Fused heterocyclic compounds as s1p modulators |
| RS63674B1 (sr) | 2016-03-18 | 2022-11-30 | Uwm Research Foundation Inc | Lečenje simptoma kognitivnih i poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 |
| UA125524C2 (uk) * | 2016-12-08 | 2022-04-13 | Ф. Хоффманн-Ля Рош Аг | Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5 |
| WO2018117196A1 (ja) * | 2016-12-20 | 2018-06-28 | 大日本住友製薬株式会社 | がん幹細胞を標的とする医薬 |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| HU231057B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt | Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| CA3120971A1 (en) | 2017-11-27 | 2019-05-31 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as pde1 inhibitors |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| IL279266B2 (en) | 2018-06-13 | 2024-03-01 | Hoffmann La Roche | New Isoxazolyl Ether History as GABA A ALPHA5 PAM |
| HU231414B1 (hu) | 2018-07-13 | 2023-08-28 | Richter Gedeon Nyrt. | Tiadiazin származékok |
| HU231333B1 (hu) | 2018-07-13 | 2023-01-28 | Richter Gedeon Nyrt | Spirokromán származékok |
| HU231478B1 (hu) | 2018-07-13 | 2024-02-28 | Richter Gedeon Nyrt. | Szubsztituált (aza)indol származékok |
| BR102019014802A2 (pt) * | 2018-07-20 | 2020-02-04 | Boehringer Ingelheim Int | difluorometil-fenil triazóis |
| HU231223B1 (hu) * | 2018-09-28 | 2022-01-28 | Richter Gedeon Nyrt. | GABAA A5 receptor modulátor hatású biciklusos vegyületek |
-
2021
- 2021-03-11 TW TW110108696A patent/TW202202495A/zh unknown
- 2021-03-25 WO PCT/IB2021/052486 patent/WO2021191838A1/en active Application Filing
- 2021-03-25 CN CN202180023958.0A patent/CN115348962A/zh active Pending
- 2021-03-25 AU AU2021244926A patent/AU2021244926A1/en active Pending
- 2021-03-25 PE PE2022002114A patent/PE20221836A1/es unknown
- 2021-03-25 KR KR1020227037372A patent/KR20220160061A/ko unknown
- 2021-03-25 CU CU2022000058A patent/CU20220058A7/es unknown
- 2021-03-25 IL IL296716A patent/IL296716A/en unknown
- 2021-03-25 JP JP2022557102A patent/JP2023520647A/ja active Pending
- 2021-03-25 BR BR112022019128A patent/BR112022019128A2/pt unknown
- 2021-03-25 CA CA3171441A patent/CA3171441A1/en active Pending
- 2021-03-25 JO JOP/2022/0219A patent/JOP20220219A1/ar unknown
- 2021-03-25 MX MX2022011933A patent/MX2022011933A/es unknown
- 2021-03-25 EP EP21715334.5A patent/EP4126859A1/en active Pending
- 2021-03-25 US US17/907,174 patent/US20240067637A1/en active Pending
- 2021-03-26 AR ARP210100754A patent/AR121666A1/es unknown
-
2022
- 2022-09-22 CL CL2022002568A patent/CL2022002568A1/es unknown
- 2022-10-18 ZA ZA2022/11414A patent/ZA202211414B/en unknown
- 2022-10-19 CO CONC2022/0014877A patent/CO2022014877A2/es unknown
- 2022-10-22 EC ECSENADI202282367A patent/ECSP22082367A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CU20220058A7 (es) | 2023-05-11 |
| IL296716A (en) | 2022-11-01 |
| WO2021191838A1 (en) | 2021-09-30 |
| CO2022014877A2 (es) | 2022-10-31 |
| PE20221836A1 (es) | 2022-11-29 |
| US20240067637A1 (en) | 2024-02-29 |
| KR20220160061A (ko) | 2022-12-05 |
| CN115348962A (zh) | 2022-11-15 |
| JP2023520647A (ja) | 2023-05-18 |
| MX2022011933A (es) | 2022-10-20 |
| TW202202495A (zh) | 2022-01-16 |
| AR121666A1 (es) | 2022-06-29 |
| ECSP22082367A (es) | 2022-11-30 |
| JOP20220219A1 (ar) | 2023-01-30 |
| CA3171441A1 (en) | 2021-09-30 |
| ZA202211414B (en) | 2023-06-28 |
| EP4126859A1 (en) | 2023-02-08 |
| BR112022019128A2 (pt) | 2022-11-08 |
| AU2021244926A1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| DOP2021000019A (es) | Inhibidores de inflamasoma nlrp3 | |
| CO2021012381A2 (es) | Compuestos tricíclicos condensados útiles como agentes anticancerígenos | |
| CO2020007218A2 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| CO6251367A2 (es) | Derivados de 6-amino-5-aril piridina-2il-carboxamida | |
| NI201900039A (es) | Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| CR10614A (es) | Derivados heterociclicos fusionados y metodos de uso | |
| CO6400220A2 (es) | Derivados de sulfonamida | |
| CO6531464A2 (es) | Morfolinotiazoles como moduladores alostéricos positivos alfa 7 | |
| UY38625A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| CO2022015054A2 (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| CL2022002568A1 (es) | Derivados de naftiridina y pirido[3,4-c]piridazina como moduladores del receptor gabaa alfa5 | |
| CL2018000783A1 (es) | Nuevos derivados de imidazo[4,5-b]piridina, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| DOP2017000018A (es) | [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| EA202190857A1 (ru) | Бициклические производные как модуляторы 5 рецепторов gabaa | |
| CO2024002844A2 (es) | Compuestos espirocíclicos | |
| CO2024005424A2 (es) | Derivados de amina bicíclicos como moduladores de receptor gabaa α5 | |
| UY38550A (es) | Compuestos inhibidores de inflamasoma nlrp3, composiciones, combinaciones y métodos relacionados | |
| AR111416A2 (es) | Compuesto terapéutico para el dolor y síntesis del compuesto | |
| DOP2007000086A (es) | Nuevos derivados de quinolinas |